Strides receives USFDA EIR for KRS Gardens, Bangalore facility

Bangalore: Strides Pharma Science Limited has announced that it has received the Establishment Inspection Report (EIR) for the inspection conducted by the USFDA in January 2020 at Company's flagship facility KRS Gardens, Bangalore. The inspection was related to specific Extended-Release applications made from the site. Receipt of EIR confirms the successful closure of the inspections.

The flagship facility in Bangalore is the largest manufacturing facility for the company with capabilities to produce finished dosage formulation products across multiple dosage formats including tablets, capsules, ointments, creams, and liquids. The facility is also capable of manufacturing complex formulations of Extended-Release tablets which is one of the focus areas for the company. Strides have a large Extended-Release portfolio for the US and other regulated markets with the capability to manufacture these products at multiple sites.

Strides had recently also received EIR for Bangalore facility from USFDA for the inspection conducted in March 2020 and the same was intimated to Stock Exchanges on March 26, 2020.

Strides, listed on the BSE Limited and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India.

The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy along with an institutional business to service donor‐funded markets. The Company's global manufacturing sites are located in India‐ Bangalore (two locations), Pondicherry, and Chennai, Singapore, Italy‐ Milan, Kenya‐ Nairobi and United States‐Florida.

The Company focusses on "difficult to manufacture" products that are sold in over 100 countries.

Read also: Strides Pharma gets USFDA EIR for its Bangalore flagship facility